nach oben

Journal of Clinical Immunology

Erschienen in:

01.05.2010

The Role of IgA and IgA Fc Receptors as Anti-Inflammatory Agents

verfasst von: Renato C. Monteiro

Erschienen in: Journal of Clinical Immunology | Sonderheft 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Materials and methods

Serum monomeric immunoglobulin A (IgA) has powerful immunomodulatory roles in its ability to suppress immune responses. Monomeric IgA acts through FcαRI, which plays a significant role in vivo in maintaining the integrity of immune responses by an inhibitory immunoreceptor tyrosine-based activation motif-mediated process and powerful inhibitory cellular effector mechanisms elicited by the IgA system.

Results

Triggering of FcαRI-mediated inhibitory function by Fab anti-FcαRI-mediated inhibitory function is able to inhibit several inflammatory and autoimmune diseases including asthma and glomerulonephritis.

Conclusion

The use of monomeric IgA as a therapeutic tool in human inflammatory diseases may offer much potential.

Kerr MA. The structure and function of human IgA. Biochem J. 1990;271:285–96.PubMed

Solomon A. Monoclonal immunoglobulins as biomarkers of cancer. Cancer Markers. 1980;1:57–87.

Phalipon A, Corthesy B. Novel functions of the polymeric Ig receptor: well beyond transport of immunoglobulins. Trends Immunol. 2003;24:55–8.CrossRefPubMed

Boehm MK, Woof JM, Kerr MA, Perkins SJ. The Fab and Fc fragments of IgA1 exhibit a different arrangement from that in IgG: a study by X-ray and neutron solution scattering and homology modelling. J Mol Biol. 1999;286:1421–47.CrossRefPubMed

Woof JM, Kerr MA. The function of immunoglobulin A in immunity. J Pathol. 2006;208:270–82.CrossRefPubMed

Monteiro RC, van de Winkel JG. IgA Fc receptors. Annu Rev Immunol. 2003;21:177–204.CrossRefPubMed

Van Epps DE, Williams Jr RC. Suppression of leukocyte chemotaxis by human IgA myeloma components. J Exp Med. 1976;144:1227–42.CrossRefPubMed

Van Epps DE, Reed K, Williams Jr RC. Suppression of human PMN bactericidal activity by human IgA paraproteins. Cell Immunol. 1978;36:363–76.CrossRefPubMed

Wilton JM. Suppression by IgA of IgG-mediated phagocytosis by human polymorphonuclear leucocytes. Clin Exp Immunol. 1978;34:423–8.PubMed

10.

Wolf HM, Fischer MB, Puhringer H, Samstag A, Vogel E, Eibl MM. Human serum IgA downregulates the release of inflammatory cytokines (tumor necrosis factor-alpha, interleukin-6) in human monocytes. Blood. 1994;83:1278–88.PubMed

11.

Nikolova EB, Russell MW. Dual function of human IgA antibodies: inhibition of phagocytosis in circulating neutrophils and enhancement of responses in IL-8-stimulated cells. J Leukoc Biol. 1995;57:875–82.PubMed

12.

Wolf HM, Hauber I, Gulle H, Samstag A, Fischer MB, Ahmad RU, et al. Anti-inflammatory properties of human serum IgA: induction of IL-1 receptor antagonist and Fc alpha R (CD89)-mediated down-regulation of tumour necrosis factor-alpha (TNF-alpha) and IL-6 in human monocytes. Clin Exp Immunol. 1996;105:537–43.CrossRefPubMed

13.

Olas K, Butterweck H, Teschner W, Schwarz HP, Reipert B. Immunomodulatory properties of human serum immunoglobulin A: anti-inflammatory and pro-inflammatory activities in human monocytes and peripheral blood mononuclear cells. Clin Exp Immunol. 2005;140:478–90.CrossRefPubMed

14.

Jacob CM, Pastorino AC, Fahl K, Carneiro-Sampaio M, Monteiro RC. Autoimmunity in IgA deficiency: revisiting the role of IgA as a silent housekeeper. J Clin Immunol. 2008;28 Suppl 1:56–61.CrossRef

15.

Pasquier B, Launay P, Kanamaru Y, Moura IC, Pfirsch S, Ruffie C, et al. Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. Immunity. 2005;22:31–42.PubMed

16.

Wines BD, Sardjono CT, Trist HH, Lay CS, Hogarth PM. The interaction of Fc alpha RI with IgA and its implications for ligand binding by immunoreceptors of the leukocyte receptor cluster. J Immunol. 2001;166:1781–9.PubMed

17.

Lawrence DA, Weigle WO, Spiegelberg HL. Immunoglobulins cytophilic for human lymphocytes, monocytes and neutrophils. J Clin Invest. 1975;55:368–72.CrossRefPubMed

18.

Grossetete B, Launay P, Lehuen A, Jungers P, Bach JF, Monteiro RC. Down-regulation of Fc alpha receptors on blood cells of IgA nephropathy patients: evidence for a negative regulatory role of serum IgA. Kidney Int. 1998;53:1321–35.CrossRefPubMed

19.

Launay P, Patry C, Lehuen A, Pasquier B, Blank U, Monteiro RC. Alternative endocytic pathway for immunoglobulin A Fc receptors (CD89) depends on the lack of FcRgamma association and protects against degradation of bound ligand. J Biol Chem. 1999;274:7216–25.CrossRefPubMed

20.

Herr AB, Ballister ER, Bjorkman PJ. Insights into IgA-mediated immune responses from the crystal structures of human FcalphaRI and its complex with IgA1-Fc. Nature. 2003;423:614–20.CrossRefPubMed

21.

Davis RS, Dennis Jr G, Odom MR, Gibson AW, Kimberly RP, Burrows PD, et al. Fc receptor homologs: newest members of a remarkably diverse Fc receptor gene family. Immunol Rev. 2002;190:123–36.CrossRefPubMed

22.

Blank U, Launay P, Benhamou M, Monteiro RC. Inhibitory ITAMs as novel regulators of immunity. Immunol Rev. 2009;232:59–71.CrossRefPubMed

23.

Launay P, Lehuen A, Kawakami T, Blank U, Monteiro RC. IgA Fc receptor (CD89) activation enables coupling to syk and Btk tyrosine kinase pathways: differential signaling after IFN-gamma or phorbol ester stimulation. J Leukoc Biol. 1998;63:636–42.PubMed

24.

Kanamaru Y, Pfirsch S, Aloulou M, Vrtovsnik F, Essig M, Loirat C, et al. Inhibitory ITAM signaling by Fc alpha RI-FcR gamma chain controls multiple activating responses and prevents renal inflammation. J Immunol. 2008;180:2669–78.PubMed

25.

Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol. 2008;26:513–33.CrossRefPubMed

Titel: The Role of IgA and IgA Fc Receptors as Anti-Inflammatory Agents
verfasst von: Renato C. Monteiro
Publikationsdatum: 01.05.2010
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe Sonderheft 1/2010
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-010-9397-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2010

Mechanisms of IVIG Efficacy in Chronic Inflammatory Demyelinating Polyneuropathy

Antibodies: Basic Mechanisms and Emerging Concepts

Immunoglobulin Responsive Chronic Pain

Cell Death Modulation by Intravenous Immunoglobulin

Naturally Occurring IgM Anti-Leukocyte Autoantibodies Inhibit T-Cell Activation and Chemotaxis

Adaptive and Innate Immune Responses in Autism: Rationale for Therapeutic Use of Intravenous Immunoglobulin